These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 16729910

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis.
    Junbo H, Li Q, Zaide W, Yunde H.
    In Vivo; 1999; 13(2):177-80. PubMed ID: 10363175
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W, Nakabayashi M, Regan MM, Oh WK.
    Cancer; 2007 Dec 15; 110(12):2709-15. PubMed ID: 17960608
    [Abstract] [Full Text] [Related]

  • 10. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.
    Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA.
    J Urol; 2001 Apr 15; 165(4):1325-8. PubMed ID: 11257710
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y.
    Prostate Cancer Prostatic Dis; 2008 Apr 15; 11(3):258-63. PubMed ID: 17876341
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T, Hara N, Kitamura Y, Komatsubara S.
    Urology; 2007 Oct 15; 70(4):702-5. PubMed ID: 17991541
    [Abstract] [Full Text] [Related]

  • 15. Prognostic and predictive significance of plasma hepatocyte growth factor and carcinoembryonic antigen in non-small lung cancer after surgery.
    Fang MY, Wang SY, Zheng YB, Gong LY, Bao WL, Gu DL, Mao WM.
    Eur Rev Med Pharmacol Sci; 2014 Oct 15; 18(3):398-403. PubMed ID: 24563441
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Levels of hepatocyte growth factor/scatter factor (HGF/SF) in seminal plasma of patients with andrological diseases.
    Depuydt CE, De Potter CR, Zalata A, Baekelandt E, Bosmans E, Comhaire FH.
    J Androl; 1998 Oct 15; 19(2):175-82. PubMed ID: 9570740
    [Abstract] [Full Text] [Related]

  • 18. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.
    Prostate Cancer Prostatic Dis; 2012 Mar 15; 15(1):75-86. PubMed ID: 21986985
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.